What Analyst Projections for Key Metrics Reveal About Steris (STE) Q4 Earnings

Core Insights - Analysts project that Steris (STE) will report quarterly earnings of $2.58 per share, reflecting a 7.1% year-over-year increase, with revenues expected to reach $1.48 billion, a 4.2% increase from the same quarter last year [1] Revenue Projections - 'Revenues- Healthcare' are projected to be $1.05 billion, indicating a 4.5% increase year-over-year [4] - 'Revenues- Healthcare Products- Service' are expected to reach $360.96 million, suggesting a 5.1% year-over-year increase [4] - 'Revenues- Healthcare Products- Capital equipment' is estimated at $327.37 million, reflecting a 1.3% decrease from the prior-year quarter [4] - 'Revenues- Healthcare Products- Consumables' are projected at $364.74 million, indicating a 9.6% year-over-year increase [5] - 'Revenues- Applied Sterilization Technologies (AST)' are expected to be $269.92 million, reflecting a 7.6% increase from the year-ago quarter [5] - 'Revenues- Life Sciences' are projected to reach $155.49 million, indicating a 3.2% decrease year-over-year [5] - 'Revenues- Life Sciences- Service' is expected to be $41.39 million, reflecting a 10% decrease year-over-year [6] - 'Revenues- Life Sciences- Consumables' are projected at $80.04 million, indicating a 13.7% year-over-year increase [6] - 'Revenues- Life Sciences- Capital equipment' is expected to be $35.43 million, reflecting a 19.9% decrease year-over-year [6] Operating Income Estimates - The consensus estimate for 'Operating income / (loss)- Healthcare' is $255.95 million, compared to $245.22 million reported in the same quarter last year [7] - 'Operating income / (loss)- Applied Sterilization Technologies (AST)' is estimated at $118.69 million, compared to $114.22 million reported in the same quarter last year [7] - The consensus for 'Operating income / (loss)- Life Sciences' is projected at $64.54 million, slightly up from $64.49 million reported in the previous year [8] Stock Performance - Steris shares have increased by 4% over the past month, while the Zacks S&P 500 composite has moved up by 13.7% [9] - With a Zacks Rank 2 (Buy), Steris is expected to outperform the overall market performance in the near term [10]